Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses

European Journal of Human Genetics

Volumn 14, Issue 7, 2006, Pages 846-852

  Piotrowska, Ewa ^a   Jakóbkiewicz Banecka, Joanna ^b   Barańska, Sylwia ^a   Tylki Szymańska, Anna ^c   Czartoryska, Barbara ^d   Wegrzyn, Alicja ^b   Wegrzyn, Grzegorz ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Gene expression targeted therapy; Genistein; Glycosaminoglycans; Isoflavones; Mucopolysaccharidoses; Substrate reduction therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; GLYCOSAMINOGLYCAN; ISOFLAVONE; PHOSPHOTRANSFERASE;

ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG TARGETING; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FIBROBLAST CULTURE; GENE EXPRESSION; GENETIC CODE; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; HUMAN CELL; HUNTER SYNDROME; HURLER SYNDROME; MUCOPOLYSACCHARIDOSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SANFILIPPO SYNDROME;

BIOPSY; CELL LINE; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENISTEIN; GLYCOSAMINOGLYCANS; HUMANS; MUCOPOLYSACCHARIDOSES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN;

EID: 33745279635     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201623     Document Type: Article

References (37)

1. Raman R, Sasisekharan V, Sasisekharan R: Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol 2005; 12: 267-277.
2. Neufeld EF, Muenzer J: The mucopolysaccharidoses; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds):: The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill Co, 2001, pp 3421-3452.
3. Wegrzyn G, Wegrzyn A, Tylki-Szymańska A: A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Med Hypoth 2004; 62: 986-992.
4. Kakkis ED, Muenzer J, Tiller GE et al: Enzyme-replacement therapy in mucopolysaccharidosis I. New Engl J Med 2001; 344: 182-188.
5. Wraith JE, Clarke LA, Beck M et al: Enzyme replacement therapy for mucopolysaccharidoses I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (Laronidase). J Pediatr 2004; 144: 581-588.
6. Wraith JE: The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005; 6: 489-506.
7. Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA: Enzyme replacement therapy in mucopolysaccharidoses type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002; 91: 98-99.
8. Harmatz P, Whitley CB, Waber L et al: Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144: 574-580.
9. Cox TM: Substrate reduction therapy for lysosomal storage diseases. Acta Pediatr Suppl 2005; 94: 69-75.
10. Sato T, Gotoh M, Kiyohara K et al: Differential roles of two N-acetylgalactosaminyltransferases, CSGalNAcT-1, and a novel enzyme, CSGalNAcT-2. J Biol Chem 2003; 278: 3063-3071.
11. Brown A, Jolly P, Wai H: Genistein modulates neuroblastoma cell proliferation and differentiation through induction of apoptosis and regulation of tyrosine kinase activity and N-myc expression. Carcinogenesis 1998; 19: 991-997.
12. Murata M, Bonassar LJ, Wright M, Mankin HJ, Towle CA: A role for the interleukin-1 receptor in the pathway linking static mechanical compression to decreased proteoglycan synthesis in surface articular cartilage. Arch Biochem Biophys 2003; 413: 229-235.
13. Bartold PM, Moule AJ, Li H, Rigby P: Isolation and characterization of the proteoglycans synthesized by adult human pulp fibroblasts in vitro. Int Endod J 1995; 28: 163-171.
14. Barbosa I, Garcia S, Barbier-Chassefiere V, Caruelle JP, Martelly I, Papy-Garcia D: Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology 2003; 13: 647-653.
15. Paradisi M, McClintock D, Boguslavsky RL, Pedicelli C, Worman HJ, Djabali K: Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress. BMC Cell Biol 2005; 6: 27.
16. Pisano MM, Greene RM: Epidermal growth factor potentiates the induction of ornithine decarboxylase activity by prostaglandins in embryonic palate mesenchymal cells: Effects on cell proliferation and glycosaminoglycan synthesis. Dev Biol 1987; 122: 419-431.
17. 1. J Biol Chem 1997; 272: 4787-4794.
18. Akiyama T, Ishida J, Nakagawa S et al: Genistein, a specific inhibitor of tyrosine-specific protein kinase. J Biol Chem 1987; 262: 5592-5595.
19. Kim H, Peterson TG, Barnes S: Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 1998; 68: 1418S-1425S.
20. Tzanakakis GN, Hjerpe A, Karamanos NK: Proteoglycan synthesis induced by transforming and basic fibroblast growth factors in human malignant mesothelioma is mediated through specific receptors and the tyrosine kinase intracellular pathway. Biochimie 1997; 79: 323-332.
21. Mitropoulou TN, Tzanakakis GN, Nikitovic D, Tsatsakis A, Karamanos NK: In vitro effects of genistein on the synthesis and distribution of glycosaminoglycans/proteoglycans by estrogen receptor-positive and -negative human breast cancer epithelial cells. Anticancer Res 2002; 22: 2841-2846.
22. Nikitovic D, Tsatsakis AM, Karamanos NK, Tzanakakis GN: The effects of genistein on the synthesis and distribution of glycosaminoglycans/ proteoglycans by two osteosarcoma cell lines depends on tyrosine kinase and the estrogen receptor density. Anticancer Res 2003; 23: 459-464.
23. Kato M, Takeda S, Ogawara S, Takayama S: Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother 1995; 39: 1979-1983.
24. Kloska A, Bohdanowicz J, Konopa G et al: Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human α-l-iduronidase (laronidase, Aldurazyme). Am J Med Genet 2005; 1390: 199-203.
25. Wegrzyn G, Kurlenda J, Liberek A et al: Atypical microbial infections of digestive tract may contribute to diarrhea in mucopolysaccharidosis patients: A MPS I case study. BMC Pediatr 2005; 5: 9.
26. Tsai TH: Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 2005; 1073: 317-322.
27. Kakkis E, McEntee M, Vogler C et al: Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 2004; 83: 163-174.
28. Vogler C, Levy B, Grubb JH et al: Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 2005; 102: 14777-14782.
29. Bloedon LT, Jeffcoat AR, Lopaczynski W et al: Safety and pharmacokinetics of purified soy isoflavones: Single-dose administration to postmenopausal women. Am J Clin Nutr 2002; 76: 1126-1137.
30. Busby MG, Jeffcoat AR, Bloedon LT et al: Clinical characteristics and pharmacokinetics of purified soy isoflavones: Single-dose administration to healthy men. Am J Clin Nutr 2002; 75: 126-136.
31. McClain RM, Wolz E, Davidovich A, Pfannkuch F, Bausch J: Subchronic and chronic safety studies with genistein in dogs. Food Chem Toxicol 2005; 43: 1461-1482.
32. Ullmann U, Metzner J, Frank T, Cohn W, Riegger C: Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers. Adv Ther 2005; 22: 65-78.
33. Fischer L, Mahoney C, Jeffcoat AR et al: Clinical characteristics and pharmacokinetics of purified soy isoflavones: Multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004; 48: 160-170.
34. Barnes S: Soy isoflavones - phytoestrogens and what else? J Nutr 2004; 134: 1225S-1228S.
35. Giampietro PG, Bruno G, Furcolo G et al: Soy protein formulas in children: No hormonal effects in long-term feeding. J Pediatr Endocrinol Metab 2004; 17: 191-196.
36. Chen A, Rogan WJ: IsoflavonesAin soy infant formula: a review of evidence for endocrine and other activity in infants. Annu Rev Nutr 2004; 24: 33-54.
37. McClain RM, Wolz E, Davidovich A, Bausch J: Genetic toxicity studies with genistein. Food Chem Toxicol 2006; 44: 42-55.